Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05953090 · ClinicalTrials.gov registry record · NA
VALOR: Vaginal Atrophy & Long-term Observation of Recovery
A NA study of Vaginal Atrophy and Genitourinary Syndrome of Menopause, sponsored by Stratpharma.
- Recruiting
- Registry status
- NA
- Development phase
- 2,000
- Enrollment target
- 14
- Study locations
NCT05953090 is a NA study of Vaginal Atrophy and Genitourinary Syndrome of Menopause that is actively recruiting participants, run by Stratpharma. The registered enrollment target is 2,000 participants, above the 134-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (1393% higher). The trial reports 14 study locations across 9 states.
The verdict
NCT05953090, a NA study of Vaginal Atrophy and Genitourinary Syndrome of Menopause, is actively recruiting participants, sponsored by Stratpharma.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,000 participants
- Enrollment target
- 14
- Study locations
Study Summary
Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.
Conditions Studied
Interventions
- DEVICE 7-0940
Study Locations (14)
California
- Velvet Clinical Research - Burbank
- Orange Coast Women's Medical Group - Laguna Hills
- WR-PRI, LLC (Los Alamitos) - Los Alamitos
- WR-PRI, LLC (Newport Beach) - Newport Beach
- WR-Women's Health Care Research, LLC - San Diego
South Carolina
- WR-Charleston Clinical Trials, LLC - Charleston
- Southern Urogynecology - West Columbia
Alabama
- Cahaba Dermatology & Skin Health Center - Birmingham
Florida
- WR-Multi-Specialty Research Associates - Lake City
Georgia
- WR-Mount Vernon Clinical Research, LLC - Sandy Springs
Nevada
- WR-Clinical Research Center of Nevada, LLC - Las Vegas
North Carolina
- WR-Carolina Institute for Clinical Research - Fayetteville
Tennessee
- WR-Medical Research Center of Memphis, LLC - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2028-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05953090
The ClinicalTrials.gov registry entry for NCT05953090 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 134-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (1393% higher). The listed sponsor is Stratpharma, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Vaginal Atrophy appearing as the primary indexed condition, and to 1 intervention - of which 7-0940 is the first listed.
NCT05953090 reports 14 study locations spanning 9 distinct geographic areas - top geographies include California, South Carolina, Alabama.
Frequently Asked Questions
What is clinical trial NCT05953090 about?
NCT05953090 is a clinical study titled "VALOR: Vaginal Atrophy & Long-term Observation of Recovery". Vulvovaginal skin conditions, namely vaginal atrophy, lichen sclerosus, lichen simplex chronicus and lichen planus affecting the female adult population will be treated with a novel gel dressing to test the short- and long-term safety and efficacy of the device.
What is the current status of trial NCT05953090?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,000 participants. The study started on 2023-10-30. Estimated completion is 2028-12.
What conditions does trial NCT05953090 study?
This clinical trial studies the following conditions: Vaginal Atrophy, Genitourinary Syndrome of Menopause, Atrophic Vaginitis, Lichen Sclerosus of Vulva, Lichen Planus of Vulva.
What interventions are being tested in trial NCT05953090?
The interventions under investigation include: 7-0940 (DEVICE).
Who is sponsoring clinical trial NCT05953090?
This trial is sponsored by Stratpharma, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05953090 being conducted?
This trial has 14 study locations across Alabama, California, Florida, Georgia, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaginal Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRP Injections for Genitourinary Syndrome of Menopause
ACTIVE NOT RECRUITING · NA
-
Hybrid Fractional Laser for Symptoms of Genitourinary Syndrome of Menopause
COMPLETED · NA
-
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
COMPLETED · NA
-
Prevention of Recurrent UTI Using Vaginal Testosterone Versus Placebo Placebo
RECRUITING · Phase 4
-
Postpartum Vaginal Estrogen for Breastfeeding Patients
RECRUITING · Phase 4
-
ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.